These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38847081)

  • 1. Novel Multiplexed Plasma Biomarker Panel Has Diagnostic and Prognostic Potential in Children With Hypertrophic Cardiomyopathy.
    Captur G; Doykov I; Chung SC; Field E; Barnes A; Zhang E; Heenan I; Norrish G; Moon JC; Elliott PM; Heywood WE; Mills K; Kaski JP
    Circ Genom Precis Med; 2024 Jun; 17(3):e004448. PubMed ID: 38847081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a Multiplex Biomarker Panel for Hypertrophic Cardiomyopathy Using Quantitative Proteomics and Machine Learning.
    Captur G; Heywood WE; Coats C; Rosmini S; Patel V; Lopes LR; Collis R; Patel N; Syrris P; Bassett P; O'Brien B; Moon JC; Elliott PM; Mills K
    Mol Cell Proteomics; 2020 Jan; 19(1):114-127. PubMed ID: 31243064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy.
    Gawor M; Śpiewak M; Janas J; Kożuch K; Wróbel A; Mazurkiewicz Ł; Baranowski R; Marczak M; Grzybowski J
    Kardiol Pol; 2017; 75(10):997-1004. PubMed ID: 28612913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of cardiac death in patients with hypertrophic cardiomyopathy using plasma adipokine levels.
    Akita K; Hasegawa K; Fifer MA; Tower-Rader A; Jung J; Maurer MS; Reilly MP; Shimada YJ
    Nutr Metab Cardiovasc Dis; 2024 Jun; 34(6):1352-1360. PubMed ID: 38403486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of coagulation and proteomics profiles in symptomatic feline hypertrophic cardiomyopathy and healthy control cats.
    Jiwaganont P; Roytrakul S; Thaisakun S; Sukumolanan P; Petchdee S
    BMC Vet Res; 2024 Jul; 20(1):292. PubMed ID: 38970022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of Proteomics Profiling for Biomarker Discovery in Hypertrophic Cardiomyopathy.
    Shimada YJ; Hasegawa K; Kochav SM; Mohajer P; Jung J; Maurer MS; Reilly MP; Fifer MA
    J Cardiovasc Transl Res; 2019 Dec; 12(6):569-579. PubMed ID: 31278493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood-based protein profiling identifies serum protein c-KIT as a novel biomarker for hypertrophic cardiomyopathy.
    Sonnenschein K; Fiedler J; de Gonzalo-Calvo D; Xiao K; Pfanne A; Just A; Zwadlo C; Soltani S; Bavendiek U; Kraft T; Dos Remedios C; Cebotari S; Bauersachs J; Thum T
    Sci Rep; 2021 Jan; 11(1):1755. PubMed ID: 33469076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel miRNA Screen Identifies miRNA-4454 as a Candidate Biomarker for Ventricular Fibrosis in Patients with Hypertrophic Cardiomyopathy.
    Thottakara T; Lund N; Krämer E; Kirchhof P; Carrier L; Patten M
    Biomolecules; 2021 Nov; 11(11):. PubMed ID: 34827715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of high-sensitivity cardiac troponin T in hypertrophic cardiomyopathy.
    Kubo T; Kitaoka H; Yamanaka S; Hirota T; Baba Y; Hayashi K; Iiyama T; Kumagai N; Tanioka K; Yamasaki N; Matsumura Y; Furuno T; Sugiura T; Doi YL
    J Am Coll Cardiol; 2013 Oct; 62(14):1252-1259. PubMed ID: 23623916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Biomarkers of Myocardial Remodeling and Coronary Dysfunction in Early Stages of Hypertrophic Cardiomyopathy in the Young.
    Fernlund E; Gyllenhammar T; Jablonowski R; Carlsson M; Larsson A; Ärnlöv J; Liuba P
    Pediatr Cardiol; 2017 Apr; 38(4):853-863. PubMed ID: 28361263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Proteomics Profiling Reveals Circulating Biomarkers of Hypertrophic Cardiomyopathy.
    Shimada YJ; Raita Y; Liang LW; Maurer MS; Hasegawa K; Fifer MA; Reilly MP
    Circ Heart Fail; 2021 Jul; 14(7):e007849. PubMed ID: 34192899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of new predictive scores for sudden cardiac death in childhood hypertrophic cardiomyopathy in a French cohort.
    Fontanges PA; Marquie C; Houeijeh A; Baudelet JB; Richard A; Amenyah C; Lucidarme S; Bonnet M; Delarue A; Bichali S; Assi NA; Marechaux S; Menet A; Vaksmann G; Godart F; Domanski O
    Arch Cardiovasc Dis; 2024; 117(6-7):402-408. PubMed ID: 38821762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CMR feature tracking strain patterns and their association with circulating cardiac biomarkers in patients with hypertrophic cardiomyopathy.
    Cavus E; Muellerleile K; Schellert S; Schneider J; Tahir E; Chevalier C; Jahnke C; Radunski UK; Adam G; Kirchhof P; Blankenberg S; Lund GK; Avanesov M; Patten M
    Clin Res Cardiol; 2021 Nov; 110(11):1757-1769. PubMed ID: 33779809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth differentiation factor 15 can distinguish between hypertrophic cardiomyopathy and hypertensive hearts.
    Hanatani S; Izumiya Y; Takashio S; Kojima S; Yamamuro M; Araki S; Rokutanda T; Tsujita K; Yamamoto E; Tanaka T; Tayama S; Kaikita K; Hokimoto S; Sugiyama S; Ogawa H
    Heart Vessels; 2014 Mar; 29(2):231-7. PubMed ID: 23525862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood-based biomarkers for the prediction of hypertrophic cardiomyopathy prognosis: a systematic review and meta-analysis.
    Jansen M; Algül S; Bosman LP; Michels M; van der Velden J; de Boer RA; van Tintelen JP; Asselbergs FW; Baas AF
    ESC Heart Fail; 2022 Oct; 9(5):3418-3434. PubMed ID: 35842920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy.
    Norrish G; Qu C; Field E; Cervi E; Khraiche D; Klaassen S; Ojala TH; Sinagra G; Yamazawa H; Marrone C; Popoiu A; Centeno F; Schouvey S; Olivotto I; Day SM; Colan S; Rossano J; Wittekind SG; Saberi S; Russell M; Helms A; Ingles J; Semsarian C; Elliott PM; Ho CY; Omar RZ; Kaski JP
    Eur J Prev Cardiol; 2022 Mar; 29(4):678-686. PubMed ID: 34718528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic Events.
    Maurizi N; Passantino S; Spaziani G; Girolami F; Arretini A; Targetti M; Pollini I; Tomberli A; Pradella S; Calabri GB; Vinattieri V; Bertaccini B; Leone O; De Simone L; Rapezzi C; Marchionni N; Cecchi F; Favilli S; Olivotto I
    JAMA Cardiol; 2018 Jun; 3(6):520-525. PubMed ID: 29710196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics of hypertrophic cardiomyopathy in children: An 8-year single center experience.
    Tunca Sahin G; Ozgur S; Kafali HC; Sevinc Sengul F; Haydin S; Guzeltas A; Ergul Y
    Pediatr Int; 2021 Jan; 63(1):37-45. PubMed ID: 32682351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scleraxis as a prognostic marker of myocardial fibrosis in hypertrophic cardiomyopathy (SPARC) study.
    Zhu A; Bews H; Cheung D; Nagalingam RS; Mittal I; Goyal V; Asselin CY; Kirkpatrick IDC; Czubryt MP; Jassal DS
    Can J Physiol Pharmacol; 2020 Jul; 98(7):459-465. PubMed ID: 32027517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Troponin as ischemic biomarker is related with all three echocardiographic risk factors for sudden death in hypertrophic cardiomyopathy (ESC Guidelines 2014).
    Hładij R; Rajtar-Salwa R; Dimitrow PP
    Cardiovasc Ultrasound; 2017 Sep; 15(1):24. PubMed ID: 28903763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.